Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Schizophrenia

  Free Subscription


Articles published in J Clin Psychopharmacol

Retrieve available abstracts of 89 articles:
HTML format
Text format



Single Articles


    December 2017
  1. COLLE R, Boichot F, Bouteiller E, Elie-Lefebvre C, et al
    Restless Legs Syndrome and Schizophrenia: A Case Report.
    J Clin Psychopharmacol. 2017 Dec 6. doi: 10.1097/JCP.0000000000000832.
    PubMed     Text format    


    November 2017
  2. ALY EL-GABRY DM, Abdel Aziz K, Okasha T, Azzam H, et al
    Antipsychotic Polypharmacy and Its Relation to Metabolic Syndrome in Patients With Schizophrenia: An Egyptian Study.
    J Clin Psychopharmacol. 2017 Nov 28. doi: 10.1097/JCP.0000000000000815.
    PubMed     Text format     Abstract available


    October 2017
  3. SANDERS LLO, Menezes CES, Chaves Filho AJM, Viana GA, et al
    alpha-Lipoic Acid as Adjunctive Treatment for Schizophrenia: An Open-Label Trial.
    J Clin Psychopharmacol. 2017 Oct 19. doi: 10.1097/JCP.0000000000000800.
    PubMed     Text format     Abstract available


  4. JOY G, Whiskey E, Bolstridge M, Porras-Segovia A, et al
    Hearts and Minds: Real-Life Cardiotoxicity With Clozapine in Psychosis.
    J Clin Psychopharmacol. 2017 Oct 19. doi: 10.1097/JCP.0000000000000792.
    PubMed     Text format     Abstract available


  5. FEELEY RJ, Arnaout B, Yoon G
    Effective Switch From Clozapine to Aripiprazole in Treatment-Resistant Schizophrenia and Comorbid Alcohol Use Disorder.
    J Clin Psychopharmacol. 2017 Oct 12. doi: 10.1097/JCP.0000000000000794.
    PubMed     Text format    


  6. NAVKHARE P, Kalra G, Saddichha S
    Possible Psychosis Associated With Buprenorphine Withdrawal.
    J Clin Psychopharmacol. 2017 Oct 9. doi: 10.1097/JCP.0000000000000803.
    PubMed     Text format    


  7. ANG MS, Abdul Rashid NA, Lam M, Rapisarda A, et al
    The Impact of Medication Anticholinergic Burden on Cognitive Performance in People With Schizophrenia.
    J Clin Psychopharmacol. 2017 Oct 9. doi: 10.1097/JCP.0000000000000790.
    PubMed     Text format     Abstract available


  8. BERESFORD T, Buchanan J, Thumm EB, Emrick C, et al
    Late Reduction of Cocaine Cravings in a Randomized, Double-Blind Trial of Aripiprazole vs Perphenazine in Schizophrenia and Comorbid Cocaine Dependence.
    J Clin Psychopharmacol. 2017 Oct 3. doi: 10.1097/JCP.0000000000000789.
    PubMed     Text format     Abstract available


    September 2017
  9. SAJATOVIC M, Ramirez LF, Fuentes-Casiano E, Cage J, et al
    A 6-Month Prospective Trial of a Personalized Behavioral Intervention + Long-Acting Injectable Antipsychotic in Individuals With Schizophrenia at Risk of Treatment Nonadherence and Homelessness.
    J Clin Psychopharmacol. 2017 Sep 19. doi: 10.1097/JCP.0000000000000778.
    PubMed     Text format     Abstract available


  10. HOJLUND M, Munk-Jorgensen P
    Differences in Antipsychotic Prescriptions Between Centers in Young Outpatients With Schizophrenia.
    J Clin Psychopharmacol. 2017 Sep 7. doi: 10.1097/JCP.0000000000000779.
    PubMed     Text format    


    August 2017
  11. ZABALA A, Bustillo M, Querejeta I, Alonso M, et al
    A Pilot Study of the Usefulness of a Single Olanzapine Plasma Concentration as an Indicator of Early Drug Effect in a Small Sample of First-Episode Psychosis Patients.
    J Clin Psychopharmacol. 2017 Aug 8. doi: 10.1097/JCP.0000000000000770.
    PubMed     Text format     Abstract available


    June 2017
  12. DOYLE R, Behan C, O'Keeffe D, Masterson S, et al
    Clozapine Use in a Cohort of First-Episode Psychosis.
    J Clin Psychopharmacol. 2017 Jun 23. doi: 10.1097/JCP.0000000000000734.
    PubMed     Text format     Abstract available


  13. SHE S, Yi W, Zhang B, Zheng Y, et al
    Worsening of Myasthenia Gravis After Administration of Antipsychotics for Treatment of Schizophrenia: A Case Report and Review of Literature.
    J Clin Psychopharmacol. 2017 Jun 20. doi: 10.1097/JCP.0000000000000741.
    PubMed     Text format    


  14. SHAO W, Brown T, Ayub S
    Phenelzine Withdrawal-Associated Psychosis and Mania.
    J Clin Psychopharmacol. 2017 Jun 13. doi: 10.1097/JCP.0000000000000739.
    PubMed     Text format    


  15. BRUNO A, Pandolfo G, Crucitti M, Cedro C, et al
    Bergamot Polyphenolic Fraction Supplementation Improves Cognitive Functioning in Schizophrenia: Data From an 8-Week, Open-Label Pilot Study.
    J Clin Psychopharmacol. 2017 Jun 6. doi: 10.1097/JCP.0000000000000730.
    PubMed     Text format     Abstract available


  16. BARMAN R, Kumar S, Pagadala B, Detweiler MB, et al
    Cocaine Abuse, Traumatic Brain Injury, and Preexisting Brain Lesions as Risk Factors for Bupropion-Associated Psychosis.
    J Clin Psychopharmacol. 2017 Jun 5. doi: 10.1097/JCP.0000000000000729.
    PubMed     Text format     Abstract available


  17. WATANABE J, Fukui N, Suzuki Y, Sugai T, et al
    Effect of GWAS-Identified Genetic Variants on Maximum QT Interval in Patients With Schizophrenia Receiving Antipsychotic Agents: A 24-Hour Holter ECG Study.
    J Clin Psychopharmacol. 2017 Jun 5. doi: 10.1097/JCP.0000000000000724.
    PubMed     Text format     Abstract available


  18. KANTROWITZ JT, Nolan KA, Epstein ML, Lehrfeld N, et al
    Neurophysiological Effects of Bitopertin in Schizophrenia.
    J Clin Psychopharmacol. 2017 Jun 5. doi: 10.1097/JCP.0000000000000722.
    PubMed     Text format     Abstract available


  19. BUCHANAN RW, Kelly DL, Weiner E, Gold JM, et al
    A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia.
    J Clin Psychopharmacol. 2017 Jun 5. doi: 10.1097/JCP.0000000000000720.
    PubMed     Text format     Abstract available


  20. ZHENG W, Wang S, Ungvari GS, Ng CH, et al
    Amantadine for Antipsychotic-Related Weight Gain: Meta-Analysis of Randomized Placebo-Controlled Trials.
    J Clin Psychopharmacol. 2017;37:341-346.
    PubMed     Text format     Abstract available


  21. LOPEZ LV, Shaikh A, Merson J, Greenberg J, et al
    Accuracy of Clinician Assessments of Medication Status in the Emergency Setting: A Comparison of Clinician Assessment of Antipsychotic Usage and Plasma Level Determination.
    J Clin Psychopharmacol. 2017;37:310-314.
    PubMed     Text format     Abstract available


    April 2017
  22. ISMAIL Z, Peters-Strickland T, Miguelez M, Baker RA, et al
    Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores.
    J Clin Psychopharmacol. 2017 Apr 5. doi: 10.1097/JCP.0000000000000710.
    PubMed     Text format     Abstract available


  23. KIM DD, Lang DJ, Warburton DE, Barr AM, et al
    Effects of Exercise on Serum Triglycerides and Symptoms of Schizophrenia.
    J Clin Psychopharmacol. 2017;37:273-274.
    PubMed     Text format    



  24. Sex Differences in Body Mass Index and Obesity in Chinese Patients With Chronic Schizophrenia: Erratum.
    J Clin Psychopharmacol. 2017;37:168.
    PubMed     Text format    


  25. KOHLER-FORSBERG O, Horsdal HT, Legge SE, MacCabe JH, et al
    Predictors of Nonhospitalization and Functional Response in Clozapine Treatment: A Nationwide, Population-Based Cohort Study.
    J Clin Psychopharmacol. 2017;37:148-154.
    PubMed     Text format     Abstract available


    March 2017
  26. HARD ML, Mills RJ, Sadler BM, Turncliff RZ, et al
    Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia.
    J Clin Psychopharmacol. 2017 Mar 27. doi: 10.1097/JCP.0000000000000691.
    PubMed     Text format     Abstract available


  27. GAHR M, Hiemke C, Connemann BJ, Schonfeldt-Lecuona C, et al
    First-Episode Psychosis Possibly due to Roxithromycin-Related Inhibition of Metabolization of Tetrahydrocannabinol.
    J Clin Psychopharmacol. 2017 Mar 21. doi: 10.1097/JCP.0000000000000707.
    PubMed     Text format    


  28. LIN CH, Lane HY
    Clotiapine Monotherapy in a Patient With Clozapine-Resistant Schizophrenia.
    J Clin Psychopharmacol. 2017 Mar 21. doi: 10.1097/JCP.0000000000000692.
    PubMed     Text format    


  29. YOSHIMURA Y, Takeda T, Kishi Y, Harada T, et al
    Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders: A Retrospective Multicenter Study.
    J Clin Psychopharmacol. 2017 Mar 17. doi: 10.1097/JCP.0000000000000689.
    PubMed     Text format     Abstract available


  30. CHEN TR, Chen YC, Ouyang WC
    Zotepine-Associated Hypothermia in a Schizophrenic Inpatient.
    J Clin Psychopharmacol. 2017 Mar 9. doi: 10.1097/JCP.0000000000000686.
    PubMed     Text format    


    February 2017
  31. GLICK ID, Davis JM, Zamora D, Ballon J, et al
    Should Antipsychotic Medications for Schizophrenia Be Given for a Lifetime?: A Naturalistic, Long-Term Follow-Up Study.
    J Clin Psychopharmacol. 2017 Feb 13. doi: 10.1097/JCP.0000000000000680.
    PubMed     Text format     Abstract available


  32. CHEN SF, Shen YC
    5-HT1A C-1019G (rs6295) Predicts Aripiprazole Treatment Response Specifically for Cognitive and Depressive Symptoms in Schizophrenia.
    J Clin Psychopharmacol. 2017;37:114-118.
    PubMed     Text format    


  33. CHANG WH, Chen KC, Lee IH, Chi MH, et al
    Unaltered Dopamine Transporter Availability in Drug-Naive Patients With Schizophrenia After 6 Months of Antipsychotics Treatment: A Naturalistic Study.
    J Clin Psychopharmacol. 2017;37:21-26.
    PubMed     Text format     Abstract available


  34. LOOK ML, Boo YL, Chin PW, Hoo FK, et al
    Risperidone-Associated Rhabdomyolysis Without Neuroleptic Malignant Syndrome: A Case Report.
    J Clin Psychopharmacol. 2017;37:105-106.
    PubMed     Text format    


  35. GOTO T, Kato M, Matsumura Y, Omata N, et al
    Scopolamine Ointment for Clozapine-Associated Sialorrhea: A Case Report.
    J Clin Psychopharmacol. 2017;37:106-107.
    PubMed     Text format    


    January 2017
  36. CITROME L
    Activating and Sedating Adverse Effects of Second-Generation Antipsychotics in the Treatment of Schizophrenia and Major Depressive Disorder: Absolute Risk Increase and Number Needed to Harm.
    J Clin Psychopharmacol. 2017 Jan 30. doi: 10.1097/JCP.0000000000000665.
    PubMed     Text format     Abstract available


  37. MOROZOVA M, Burminskiy D, Rupchev G, Lepilkina T, et al
    5-HT6 Receptor Antagonist as an Adjunct Treatment Targeting Residual Symptoms in Patients With Schizophrenia: Unexpected Sex-Related Effects (Double-Blind Placebo-Controlled Trial).
    J Clin Psychopharmacol. 2017 Jan 30. doi: 10.1097/JCP.0000000000000673.
    PubMed     Text format     Abstract available


    December 2016
  38. CHAN HY, Pan YJ, Chen JJ, Chen CH, et al
    Time to Discontinuation of Second-Generation Antipsychotics Versus Haloperidol and Sulpiride in People With Schizophrenia: A Naturalistic, Comparative Study.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available


  39. LI Q, Chen D, Liu T, Walss-Bass C, et al
    Sex Differences in Body Mass Index and Obesity in Chinese Patients With Chronic Schizophrenia.
    J Clin Psychopharmacol. 2016;36:643-648.
    PubMed     Text format     Abstract available


  40. ENGLISCH S, Jung HS, Lewien A, Becker A, et al
    Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders: An Open-Prospective Proof-of-Concept Study.
    J Clin Psychopharmacol. 2016;36:597-607.
    PubMed     Text format     Abstract available


    October 2016
  41. ENGLISCH S, Jung HS, Lewien A, Becker A, et al
    Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders: An Open-Prospective Proof-of-Concept Study.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available


  42. ZHENG W, Zheng YJ, Li XB, Tang YL, et al
    Efficacy and Safety of Adjunctive Aripiprazole in Schizophrenia: Meta-Analysis of Randomized Controlled Trials.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available


  43. MAN SC, Li XB, Wang HH, Yuan HN, et al
    Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Women With Schizophrenia: A Randomized Controlled Trial.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available


  44. GAO K, Fang F, Wang Z, Calabrese JR, et al
    Subjective Versus Objective Weight Gain During Acute Treatment With Second-Generation Antipsychotics in Schizophrenia and Bipolar Disorder.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available


  45. FJUKSTAD KK, Engum A, Lydersen S, Dieset I, et al
    Metabolic Abnormalities Related to Treatment With Selective Serotonin Reuptake Inhibitors in Patients With Schizophrenia or Bipolar Disorder.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available


  46. CHEN WY, Lin SK
    Comparison of Subjective Experiences and Effectiveness of First-Generation Long-Acting Injectable Antipsychotics and Risperidone Long-Acting Injectables in Patients With Schizophrenia.
    J Clin Psychopharmacol. 2016;36:492-5.
    PubMed     Text format     Abstract available


  47. STRUBE W, Kirsch B, Padberg F, Hasan A, et al
    Transcranial Direct Current Stimulation as Monotherapy for the Treatment of Auditory Hallucinations During Pregnancy: A Case Report.
    J Clin Psychopharmacol. 2016;36:534-5.
    PubMed     Text format    


  48. BUZINA N, Eterovic M
    Life-Threatening Lupus-Like Syndrome Associated With Clozapine.
    J Clin Psychopharmacol. 2016;36:532-4.
    PubMed     Text format    


  49. JAKOBSEN KD, Bruhn CH, Pagsberg AK, Fink-Jensen A, et al
    Neurological, Metabolic, and Psychiatric Adverse Events in Children and Adolescents Treated With Aripiprazole.
    J Clin Psychopharmacol. 2016;36:496-9.
    PubMed     Text format     Abstract available


    September 2016
  50. EDLINGER M, Rettenbacher MA, Kemmler G, Biedermann F, et al
    Prescribing Practice in Inpatients Versus Outpatients With Schizophrenia Initiating Treatment With Second-Generation Antipsychotics: A Naturalistic Follow-Up Study.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available


  51. BOERMAN R, Cohen D, Schulte PF, Nugter A, et al
    Prevalence of Vitamin D Deficiency in Adult Outpatients With Bipolar Disorder or Schizophrenia.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available


  52. GONZALEZ-RODRIGUEZ A, Catalan R, Penades R, Ruiz Cortes V, et al
    Antipsychotic Response Worsens With Postmenopausal Duration in Women With Schizophrenia.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available


    August 2016
  53. THAMIZH JS, Menon V, Selvakumar N, Rajkumar RP, et al
    Treatment-Emergent Psychosis With Disulfiram in a Patient With Late-Onset Alcohol Use Disorder and No Contributory Factors.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format    


  54. HIRAKAWA H, Terao T, Tanaka T, Sato H, et al
    A Case of Mutism in Noncatatonic Schizophrenia Responding to Small Dose of Fluvoxamine Addition to Clozapine.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format    


    July 2016
  55. MISIAK B, Frydecka D, Beszlej JA, Samochowiec A, et al
    Effects of Antipsychotic Treatment on Depressive Symptoms With Respect to Genetic Polymorphisms Related to Dopaminergic and Serotoninergic Neurotransmission in Schizophrenia Patients.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format    


    June 2016
  56. GARCIA S, Martinez-Cengotitabengoa M, Lopez-Zurbano S, Zorrilla I, et al
    Adherence to Antipsychotic Medication in Bipolar Disorder and Schizophrenic Patients: A Systematic Review.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available


  57. SUZUKI H, Hibino H, Inoue Y, Takaya A, et al
    Comparison of Treatment Retention Between Risperidone Long-Acting Injection and First-Generation Long-Acting Injections in Patients With Schizophrenia for 5 Years.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format    


  58. FIGUEIREDO T, Segenreich D, Mattos P
    Fluoxetine Adjunctive Therapy for Obsessive-Compulsive Symptoms Associated With Olanzapine in Schizophrenic Patients.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format    


  59. ANIL YAGCIOGLU AE, Yoca G, Ayhan Y, Karaca RO, et al
    Relation of the Allelic Variants of Multidrug Resistance Gene to Agranulocytosis Associated With Clozapine.
    J Clin Psychopharmacol. 2016;36:257-61.
    PubMed     Text format     Abstract available


  60. LANGLEY-DEGROOT M, Joshi Y, Lehman D, Rao S, et al
    Atypical Neuroleptic Malignant Syndrome Associated With Paliperidone Long-Acting Injection: A Case Report.
    J Clin Psychopharmacol. 2016;36:277-9.
    PubMed     Text format    


  61. BARAK N, Beck Y, Albeck JH
    A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Betahistine to Counteract Olanzapine-Associated Weight Gain.
    J Clin Psychopharmacol. 2016;36:253-6.
    PubMed     Text format     Abstract available


  62. KREININ A, Miodownik C, Mirkin V, Gaiduk Y, et al
    Double-Blind, Randomized, Placebo-Controlled Trial of Metoclopramide for Hypersalivation Associated With Clozapine.
    J Clin Psychopharmacol. 2016;36:200-5.
    PubMed     Text format     Abstract available


  63. STRUYE A, Depuydt C, Abdel Sater E, Dubois V, et al
    Toxic Epidermal Necrolysis Related to Paliperidone Palmitate: First Case Report.
    J Clin Psychopharmacol. 2016;36:279-82.
    PubMed     Text format    


    May 2016
  64. OH N, See YM, Remington G, Lee J, et al
    Association Between Weight Gain and Remission Status at 3 Months in First-Episode Schizophrenia.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format    


    April 2016
  65. ROSSO G, Pessina E, Martini A, Di Salvo G, et al
    Paliperidone Palmitate and Metabolic Syndrome in Patients With Schizophrenia: A 12-Month Observational Prospective Cohort Study.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available


  66. SCHWARTZ DL
    Quercetin as an Augmentation Agent in Schizophrenia.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format    


  67. SCANGOS KW, Caton M, Newman WJ
    Multiple Long-Acting Injectable Antipsychotics for Treatment-Resistant Schizophrenia: Case Report.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format    


  68. LLOYD H, Deng C
    Interaction of Dopamine D2 and 5-HT1A Receptor Partial Agonism on Antipsychotic Efficacy.
    J Clin Psychopharmacol. 2016;36:192-3.
    PubMed     Text format    


  69. GONZALEZ-PABLOS E, Valles-de la Calle JM, Iglesias-Santa Polonia F, Camara Barrio S, et al
    A Case Report of Camptocormia Coinciding With Olanzapine Use.
    J Clin Psychopharmacol. 2016;36:183-4.
    PubMed     Text format    


  70. TOURNIKIOTI K, Douzenis A, Antoniadou A, Papazahos K, et al
    Eosinophilia Associated With Olanzapine.
    J Clin Psychopharmacol. 2016;36:180-1.
    PubMed     Text format    


  71. LAU SL, Muir C, Assur Y, Beach R, et al
    Predicting Weight Gain in Patients Treated With Clozapine: The Role of Sex, Body Mass Index, and Smoking.
    J Clin Psychopharmacol. 2016;36:120-4.
    PubMed     Text format     Abstract available


  72. SILVA MA, Key S, Han E, Malloy MJ, et al
    Acute Pancreatitis Associated With Antipsychotic Medication: Evaluation of Clinical Features, Treatment, and Polypharmacy in a Series of Cases.
    J Clin Psychopharmacol. 2016;36:169-72.
    PubMed     Text format     Abstract available


  73. USTOHAL L, Mayerova M, Valkova B, Sedlakova H, et al
    Asymptomatic Elevation of Amylase and Lipase After Olanzapine Treatment.
    J Clin Psychopharmacol. 2016;36:181-3.
    PubMed     Text format    


  74. LEUNG JG, Nelson S, Barreto JN, Schiavo DN, et al
    Necrotizing Pneumonia in the Setting of Elevated Clozapine Levels.
    J Clin Psychopharmacol. 2016;36:176-8.
    PubMed     Text format    


  75. GURRERA RJ, Parlee AC, Perry NL
    Aspiration Pneumonia: An Underappreciated Risk of Clozapine Treatment.
    J Clin Psychopharmacol. 2016;36:174-6.
    PubMed     Text format    


    February 2016
  76. SCHULTE PF, Bocxe JT, Doodeman HJ, van Haelst IM, et al
    Risk of New-Onset Diabetes After Long-Term Treatment With Clozapine in Comparison to Other Antipsychotics in Patients With Schizophrenia.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available


  77. BOGERS JP, Schulte PF, Van Dijk D, Bakker B, et al
    Clozapine Underutilization in the Treatment of Schizophrenia: How Can Clozapine Prescription Rates Be Improved?
    J Clin Psychopharmacol. 2016.
    PubMed     Text format    


  78. NASSER AF, Henderson DC, Fava M, Fudala PJ, et al
    Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available


  79. COMACCHIO C, Dusi N, Lasalvia A
    Successful Use of Single Doses of Granulocyte-Colony Stimulating Factor (G-CSF) in the Treatment of Late-Onset Agranulocytosis Associated With Clozapine in a Patient With Treatment-Resistant Schizophrenia: A Case Report.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format    


  80. BO QJ, Li XB, Wang ZM, Li AN, et al
    Extrapyramidal Symptoms During Risperidone Maintenance Treatment in Schizophrenia: A Prospective, Multicenter Study.
    J Clin Psychopharmacol. 2016.
    PubMed     Text format     Abstract available



  81. Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Satiety Signaling in Overweight People With Schizophrenia: Erratum.
    J Clin Psychopharmacol. 2016;36:26.
    PubMed     Text format    


  82. YOSHIMURA B, Kishi Y
    Hospitalization Risk Before and After Discontinuation of Long-Acting Injectable Antipsychotics.
    J Clin Psychopharmacol. 2016;36:86-7.
    PubMed     Text format    


    December 2015
  83. SENDA M, Bessho K, Oshima E, Sakamoto S, et al
    Anti-Inflammatory Therapy and Immunotherapy Were Partially Effective in a Patient With Anti-N-Methyl-D-Aspartate Receptor Antibodies and a Special Subgroup of Treatment-Resistant Schizophrenia.
    J Clin Psychopharmacol. 2015.
    PubMed     Text format    


  84. SHOJA SHAFTI S, Akbari S
    Intractability of Deficit Syndrome of Schizophrenia Against Adjunctive Modafinil.
    J Clin Psychopharmacol. 2015.
    PubMed     Text format     Abstract available


    April 2015
  85. MBSC EN, Joshua N, Morgan C, Rossell SL, et al
    The effect of ketamine on configural facial processing.
    J Clin Psychopharmacol. 2015;35:188-91.
    PubMed     Text format     Abstract available


  86. GONZALEZ-RODRIGUEZ A, Molina-Andreu O, Penades R, Bernardo M, et al
    Therapeutic approach to delusional disorder based on psychopathological complexity: proposal for a decision model.
    J Clin Psychopharmacol. 2015;35:201-2.
    PubMed     Text format    


  87. KANG SG, Na KS, Lee HJ, Chee IS, et al
    DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks' amisulpride treatment.
    J Clin Psychopharmacol. 2015;35:158-62.
    PubMed     Text format     Abstract available


  88. CALIGIURI MP, Teulings HL, Dean CE, Lohr JB, et al
    A quantitative measure of handwriting dysfluency for assessing tardive dyskinesia.
    J Clin Psychopharmacol. 2015;35:168-74.
    PubMed     Text format     Abstract available


    February 2015
  89. TAKAHASHI T, Masuya Y, Ueno K, Watanabe K, et al
    Clozapine-Related Negative Myoclonus Associated With Urinary Tract Infection: A Case Report.
    J Clin Psychopharmacol. 2015.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: